Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Cowen

ME Staff
-
0

Analyst Ratings For Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Today, Cowen reiterated its Buy rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI).

There are 10 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.

The current consensus rating on Aerie Pharmaceuticals Inc (NASDAQ:AERI) is Buy with a consensus target price of $79.10 per share, a potential 71.47% upside.

Some recent analyst ratings include

  • 2/27/2019-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Cowen
  • 2/8/2019-Aerie Pharmaceuticals Inc (NASDAQ:AERI) had its Buy rating reiterated by Mizuho
  • 11/12/2018-Aerie Pharmaceuticals Inc (NASDAQ:AERI) has coverage initiated with a Outperform ➝ Reduce rating and $64.00 price target
  • On 2/1/2019 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $46.17 per share and the total transaction amounting to $507,870.00.
  • On 1/2/2019 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $35.21 per share and the total transaction amounting to $387,310.00.
  • On 12/3/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $39.81 per share and the total transaction amounting to $437,910.00.
  • On 11/16/2018 Gerald D Cagle, Director, bought 2,000 with an average share price of $41.75 per share and the total transaction amounting to $83,500.00.
  • On 11/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $53.87 per share and the total transaction amounting to $592,570.00.
  • On 10/1/2018 Casey C Kopczynski, Insider, sold 11,000 with an average share price of $60.56 per share and the total transaction amounting to $666,160.00.
  • On 9/27/2018 Richard J Rubino, CFO, sold 66,605 with an average share price of $60.23 per share and the total transaction amounting to $4,011,619.15.

About Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company's advanced-stage product candidate is Roclatan, a once-daily eye drop to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Recent Trading Activity for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Shares of Aerie Pharmaceuticals Inc closed the previous trading session at 46,13 up +5,95 14,81 % with 49.07 shares trading hands.